A5082997476- Inflammatory Bowel Disease
- Microscopic Colitis
- Autoimmune and Inflammatory Disorders Research
- Adolescent and Pediatric Healthcare
- Eosinophilic Esophagitis
- Helicobacter pylori-related gastroenterology studies
- Inflammasome and immune disorders
- Immunodeficiency and Autoimmune Disorders
- IL-33, ST2, and ILC Pathways
- Autoimmune and Inflammatory Disorders
- Pharmaceutical studies and practices
- Diagnosis and treatment of tuberculosis
- Gastroesophageal reflux and treatments
- Family and Disability Support Research
- Childhood Cancer Survivors' Quality of Life
- Kawasaki Disease and Coronary Complications
- Colorectal Cancer Treatments and Studies
- Growth Hormone and Insulin-like Growth Factors
- Anorectal Disease Treatments and Outcomes
- Pituitary Gland Disorders and Treatments
- Child and Adolescent Health
- Hepatocellular Carcinoma Treatment and Prognosis
- Celiac Disease Research and Management
- Biosimilars and Bioanalytical Methods
- Systemic Sclerosis and Related Diseases
Janssen (United States)
2021-2024
Royal Free London NHS Foundation Trust
2022
Novartis (United States)
2016-2021
Tris Pharma (United States)
2017
Ipsen (France)
2013-2014
University of North Carolina at Chapel Hill
2014
Johns Hopkins Medicine
2014
Johns Hopkins University
2014
AbbVie (United States)
2013
Abbott Fund
2009-2012
<h3>Objective:</h3> To evaluate the efficacy of adalimumab in healing draining fistulas patients with active Crohn's disease (CD). <h3>Design:</h3> A phase III, multicentre, randomised, double-blind, placebo controlled study an open-label extension was conducted 92 sites. <h3>Patients:</h3> subgroup adults moderate to severely CD (CD activity index 220–450) for ⩾4 months who had at baseline. <h3>Interventions:</h3> All received initial induction therapy (80 mg/40 mg weeks 0/2). At week 4,...
Aliment Pharmacol Ther 2010; 32: 1228–1239 Summary Background Adalimumab induces and maintains remission in adults with Crohn’s disease. Aim To evaluate safety, fistula healing, quality of life work productivity adalimumab‐treated patients who failed infliximab, including primary nonresponders. Methods After a ≥8‐week infliximab washout, moderate‐to‐severe disease received open‐label adalimumab as induction (160/80 mg at weeks 0/2) maintenance (40 every other week) therapies. At/after 8...
Background and aims: We examined the impact of disease duration on clinical outcomes safety in a post hoc analysis remission maintenance trial with adalimumab patients moderate to severe CD.
Adalimumab has been shown to be efficacious and well-tolerated in Western patients with Crohn's disease. These 2 randomized, double-blind clinical trials evaluated adalimumab efficacy safety Japanese moderate severe disease.90 enrolled the induction trial were randomized receive 160/80 mg, 80/40 mg or placebo at Weeks 0/2. At Week 4, who achieved a decrease CDAI ≥ 70 points versus Baseline entered maintenance 40 every other week for 52 weeks. All received 4 more weeks of blinded before...
BackgroundDrug concentration monitoring may be useful to guide therapeutic adjustments for anti–tumor necrosis factor agents in Crohn's disease. The relationship between serum adalimumab concentrations and clinical outcomes was assessed using data from CLinical Assessment of Adalimumab Safety Efficacy Studied as Induction Therapy Disease (CLASSIC) I/II.
To compare outcomes of induction dosing followed by continuous adalimumab treatment with those reinitiation (in the event clinical deterioration) for patients moderate-to-severe Crohn's disease (CD) who participated in Trial Fully Human Antibody Adalimumab Remission Maintenance (CHARM).In CHARM trial, all received open-label therapy 80 mg and 40 at weeks 0 2, respectively. In total, 778 were randomized week 4 to one three groups: (1) placebo after initial doses (followed therapy); (2)...
Objective Periodic fever syndrome (PFS) conditions are characterized by recurrent attacks of and localized inflammation. This study examined the diagnostic pathway treatments at tertiary centers for familial Mediterranean (FMF), tumor necrosis factor receptor–associated periodic (TRAPS), mevalonate kinase deficiency (MKD)/hyperimmunoglobulinemia D (HIDS). Methods PFS specialists medical in US, European Union, eastern participated a retrospective chart review, providing de‐identified data an...
Lanreotide depot (LD; commercial name Somatuline(®) Depot) is an injectable, extended-release formulation of the synthetic somatostatin analog (SSA) lanreotide. In recent clinical trials, LD was found to be suitable for self or partner administration, avoiding need travel a medical facility. The Depot Acromegaly (SODA) study ongoing, multicenter, observational in US investigating efficacy, safety, convenience and symptom relief provided by patients with acromegaly. Sub-analyses explore...
Abstract Data on the use of golimumab (GLM) during pregnancy are limited. This study evaluated outcomes in women treated with GLM pregnancy. Cumulative data GLM‐exposed pregnancies from Company's global safety database (GSD) summarized. Cases were medically confirmed maternal exposures to or within 3 months prior conception a reported outcome. Pregnancy (e.g., live births) and congenital anomalies prospectively cases (i.e., outcome not known when first company) presented descriptive manner....
Purpose: Acromegaly is a chronic condition resulting from growth hormone-secreting pituitary tumor that can substantially impact patients' physical and emotional well-being. We sought to understand the of acromegaly on disease-related concerns treatment choices patient perspective. The path diagnosis, current disease management, interactions with treating health care providers (HCPs), support networks were also assessed. Methods: patients recruited primarily group (Acromegaly Community). In...
Limited data are available on the experiences of patients with autoinflammatory diseases (AIDs) and their families along path to diagnosis treatment. We sought describe these in AIDs including tumor necrosis factor receptor-associated periodic syndrome (TRAPS), mevalonate kinase deficiency/hyperimmunoglobulin D (MKD/HIDS), familial Mediterranean fever (FMF). Ninety-minute, semi-structured qualitative interviews 5-day written/video diaries were used gather information families. Twelve from US...
<h3>Introduction</h3> We explored the relationship between early deep remission and rates of dosage adjustment for patients (pts) with Crohn9s disease (CD). <h3>Methods</h3> EXTEND studied effects adalimumab (ADA) on mucosal healing in pts moderate to severe ileocolonic CD (CDAI 220–450). Pts received open-label (OL) ADA 160-/80-mg induction therapy at weeks 0/2 were randomised week 4 maintenance 40 mg every other (eow) or placebo through 52. From 8, flares non-response could receive OL eow....
To describe the extrapolation approaches used to support intravenous (IV) golimumab for polyarticular juvenile idiopathic arthritis (pJIA) and psoriatic (jPsA) subcutaneous (SC) ustekinumab jPsA.Pharmacokinetic, clinical response, safety data from trials of IV SC in polyarticular-course JIA (pc-JIA) (GO-VIVA) or pediatric psoriasis (PsO) (CADMUS CADMUS Jr) pivotal, phase 3 these agents adults with similar diseases were pJIA jPsA. In GO-VIVA trial, patients pc-JIA aged 2 < 18 years received...
To understand the experience of adolescent systemic juvenile idiopathic arthritis (SJIA) patients and those their parents based on social media posts.English language posts related to SJIA, Still's disease, or were collected analyzed.In total, 71 created between 2009 2015 15 websites identified in November 2015. Of 32 unique authors, 17 SJIA aged 13-20 years (40 posts), 7 mothers (12 8 had unspecified forms (19 posts). Many posted about similar diagnostic experiences marked by 5 phases: 1)...